Resource Center
Resource Center
Aurobindo Pharma Limited is pleased to announce the tentative approval of Dolutegravir 50mg from US Food & Drug Administration (USFDA) for the treatment of HIV. This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an integrase strand transfer inhibitor recommended for use in treatment-naïve patients by the US...
Read moreThe Clinton Health Access Initiative, Inc. (“CHAI”) was founded in 2002 as a Clinton Foundation Initiative. Today, the CHAI Board of Directors, which is fully committed to and proud of CHAI’s life-saving work, announced the following changes will be implemented if Secretary Clinton is elected President of the United States: The five members of CHAI’s Board...
Read moreIn 2019, updates to historical datasets were made upon consultation with relevant current suppliers, including the addition of a new supplier’s data. Please find the most up-to-date report here. The 2016 Family Planning Market Report can be found below.
Read moreThe 2015 Annual Report highlights CHAI’s programmatic work around the world, thanks to our many dedicated partners and supporters.
Read moreMwai Banda, an 18 year-old woman from Chigodi village in Kasungu District, Malawi has traveled 60 kilometers to be interviewed for a Community Midwife Assistant (CMA) training program. Mwai holds a Malawi School Certificate of Education and has always dreamt of working to improve health in her community. “There are a lot of problems in...
Read moreSee the video here. Diarrhea is the second leading killer of children worldwide, responsible for over 600,000 deaths each year. India bears a quarter of the global burden: nearly 400 children die of diarrhea each day. A highly effective treatment—zinc and oral rehydration salts (ORS)—is affordable and available, but too few children are receiving the...
Read moreView the Clinton Health Access Initiative, Inc. and Subsidiaries’ Consolidated Financial Statements for 2015.
Read moreLast World Hepatitis Day, we announced that CHAI, with the support of DFID, was launching its program in viral hepatitis to address the massive burdens of hepatitis B and C. Over this first year, we have seen tremendous progress in the global response to viral hepatitis. We have seen the release of new WHO treatment...
Read moreIn Kanchin State, a remote part of northern Myanmar, 24 year-old U Dee Se has used heroin since the age of 18. Like many other people who inject drugs (PWIDs) in the area, throughout his drug use, he shared needles with friends, but was unconcerned about potentially contracting HIV. “My body was asking for the...
Read moreIncreasing access to accurate, validated diagnostics in the private sector is key to reducing India’s high tuberculosis burden. CHAI facilitated a partnership between private sector laboratories and manufacturers to support adoption of a low-price, high-volume model that improves access to quality diagnostics and strengthens linkages in India’s healthcare system. Learn more by reading the case...
Read more